Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab SC vs IV in Relapsed Extensive-Stage Small Cell Lung Cancer
NCT07778316Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Curve From Cycle 2 Day 1 to Day 15 of Tarlatamab and Predose Concentration of Tarlatamab. Started Aug 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07778316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778316.